Form 4: Amylyx CFO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals CFO James M. Frates sold 10,558 shares of common stock on September 30, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported a sale of common stock.
• The transaction occurred on September 30, 2025.
• A total of 10,558 shares of common stock were disposed of.
• The shares were sold at a weighted average price of $14.6477 per share, with individual transaction prices ranging from $14.35 to $15.075.
• The sale was automatic and non-discretionary, executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Frates directly beneficially owns 280,430 shares of common stock.
• Additionally, 15,459 shares are held indirectly by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, and 11,072 shares by the FRATES FAMILY 2013 IRREV TRUST, for which Mr. Frates serves as trustee.

Sentiment

Score: 5

Explanation: The transaction is a routine, automatic sale of shares to cover tax withholding obligations upon RSU vesting, which is a neutral event and does not reflect discretionary selling based on company performance or outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reported shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.
• The Reporting Person disclaims beneficial ownership of shares held by trusts for purposes of Section 16 except to the extent of his pecuniary interest therein, if any.

Industry Context

This routine insider transaction, specifically a tax-related sale, does not provide insights into broader industry trends or competitive positioning for Amylyx Pharmaceuticals.

Related Party Transactions

• 15,459 shares are held indirectly by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant.
• 11,072 shares are held indirectly by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, James M. Frates, Chief Financial Officer, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Corporate Governance